Internal Medicine - Follow Up

Internal Medicine - Follow Up Reason for Referral Patient, a 58-year-old male, was referred by "Dr. Sarah Chen" for follow-up of newly diagnosed hypertension and type 2 diabetes mellitus. He presented with fatigue and occasional headaches. Update The 58-year-old patient has been managing newly diagnosed hypertension and type 2 diabetes mellitus for the past three months. His blood pressure has shown some improvement with lifestyle modifications, but his blood glucose levels remain elevated despite dietary changes. He reports occasional mild headaches, which he attributes to stress. He is currently taking Metformin 500mg twice daily and Ramipril 5mg once daily. He has not experienced any significant side effects from his current medications. Physical Examination Vital signs today are: Blood Pressure 145/92 mmHg, Pulse 78 bpm, Respiratory Rate 16 bpm, Temperature 36.8°C. General appearance is well. Cardiovascular examination reveals regular S1 and S2, no murmurs, rubs, or gallops. Lungs are clear to auscultation bilaterally, no wheezes or crackles. Abdomen is soft, non-tender, non-distended, with normoactive bowel sounds. Neurological examination is grossly intact with no focal deficits. Skin is warm and dry, no rashes or lesions observed. Summary Key points discussed with the patient included the importance of continued adherence to his medication regimen and dietary modifications for better glycaemic control and blood pressure management. The patient expressed understanding of the need for regular exercise and agreed to monitor his blood glucose levels more frequently. He was advised to continue with his current medications: Metformin 500mg twice daily and Ramipril 5mg once daily. A referral to a dietician was made to provide more targeted dietary advice. Plans for follow-up were made for one month to review blood pressure and glucose readings. Plan 1. Continue Metformin 500mg twice daily and Ramipril 5mg once daily. 2. Referral to a dietician for comprehensive dietary counselling. 3. Follow-up appointment scheduled for 1 November 2024 to review progress and lab results.